Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30407118 | 0.77 | KDM4E (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL293045 | 0.76 | KDM4E (0.37) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15761031 | 0.76 | KDM4E (0.37) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL30485934 | 0.76 | KDM4E (0.37) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL30096256 | 0.76 | KDM4E (0.38) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3069884 | 0.74 | KDM4E (0.37) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL276958 | 0.74 | P2RY6 (0.34) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL57274 | 0.74 | MAOA (0.35) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1077043 | 0.74 | P2RY6 (0.34) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2006247 | 0.74 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1014790-B | PROCESS FOR PREPARING NOVEL BENZOXAZOL-AND BENZOTHIAZOLAMINE DERIVATIVES AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 1991-11-20 | — | — | CN | claimed |
| EP-0184257-B1 | BENZOXAZOL- AND BENZOTHIAZOLAMINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-25 | — | — | EP | claimed |
| US-4861785-A | Benzoxazol-and benzothiazolamine derivatives, useful as anti-anoxic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-08-29 | — | — | US | claimed |
| CN-85108556-A | The preparation method of novel benzoxazol base and benzothiazolyl amino derivative and application thereof | — | 1986-07-30 | — | — | CN | claimed |
| EP-0184257-A1 | Benzoxazol- and benzothiazolamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-06-11 | — | — | EP | claimed |
| EP-3131897-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3131896-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-30 | — | — | EP | disclosed |
| US-9969724-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9808445-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170129880-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME LLC | 2017-05-11 | — | — | US | disclosed |
| EP-3131896-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-3131897-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-22 | — | — | EP | disclosed |
| CN-1366523-A | Process for preparing amic acid esters | IHARA CHEMICAL IND CO (JP) | 2002-08-28 | — | — | CN | disclosed |
| EP-1182199-A1 | PROCESS FOR PREPARING AMIC ACID ESTERS | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2002-02-27 | — | — | EP | disclosed |
| CN-1014790-B | PROCESS FOR PREPARING NOVEL BENZOXAZOL-AND BENZOTHIAZOLAMINE DERIVATIVES AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 1991-11-20 | — | — | CN | disclosed |
| US-5010198-A | Intermediates for the synthesis of benzoxazol- and benzothiazolamine derivatives, useful as anti-anoxic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-04-23 | — | — | US | disclosed |
| EP-0184257-B1 | BENZOXAZOL- AND BENZOTHIAZOLAMINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-25 | — | — | EP | disclosed |
| US-4861785-A | Benzoxazol-and benzothiazolamine derivatives, useful as anti-anoxic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-08-29 | — | — | US | disclosed |
| CN-85108556-A | The preparation method of novel benzoxazol base and benzothiazolyl amino derivative and application thereof | — | 1986-07-30 | — | — | CN | disclosed |
| EP-0184257-A1 | Benzoxazol- and benzothiazolamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129880-A1 | FACTOR IXa INHIBITORS | F9, F12, TFPI | KDM4E 837/4885MEN1 1911/4885ALDH1A1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.